<div id="readability-page-1"><p>Wedbush analyst David Nierengarten reiterated a Buy rating on Generation Bio today and set a price target of $5.50.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, Nierengarten is a 5-star analyst with an average return of <span>18.7%</span> and a 49.48% success rate. Nierengarten covers the Healthcare sector, focusing on stocks such as Argenx Se, Oric Pharmaceuticals, and AnaptysBio.</p> <p>Generation Bio has an analyst consensus of Moderate Buy, with a price target consensus of $5.25.</p></div>

GBIO

<p>Wedbush analyst David Nierengarten reiterated a Buy rating on Generation Bio, setting a price target of $5.50. Nierengarten, a 5-star analyst with an 18.7% average return, focuses on the Healthcare sector. Generation Bio has a Moderate Buy consensus with a $5.25 price target. This reflects investment research insights.</p>

Generation Bio (GBIO) Receives a Buy from Wedbush